MAP2K1 and breast cancer: Targeting MEK1 in conjunction with hormonal therapy as an initial treatment option would be a new approach and should be considered, because the recurrence of breast cancer in women receiving SERMs is still a major clinical challenge, and a large number of ER+ breast cancers are initially resistant to antiestrogen therapy, possibly due to IGF-1-mediated survival effects [56].